Targeting Protein–Protein Interactions to Treat Cancer—Recent Progress and Future Directions
Authors:
- William GarlandWGWilliam Garland
- Robert BenezraRBRobert Benezra
- Jaideep ChaudharyJCJaideep Chaudhary
- 1 January 2013
- book chapter
- Published by Elsevier
- p. 227-245
Abstract
No abstract availableThis publication has 74 references indexed in Scilit:
- Id1 and Id3 expression is associated with increasing grade of prostate cancer: Id3 preferentially regulates CDKN1BCancer Medicine, 2012
- Wnt/β-Catenin Signaling and DiseaseCell, 2012
- Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152)Journal of Medicinal Chemistry, 2012
- Chemical and structural lessons from recent successes in protein–protein interaction inhibition (2P2I)Current Opinion in Chemical Biology, 2011
- Interactome Networks and Human DiseaseCell, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Selective inhibition of BET bromodomainsNature, 2010
- Expanding the range of ‘druggable’ targets with natural product-based libraries: an academic perspectiveCurrent Opinion in Chemical Biology, 2010
- An empirical framework for binary interactome mappingNature Methods, 2008
- Evaluation of “Credit Card” Libraries for Inhibition of HIV-1 gp41 Fusogenic Core FormationJournal of Combinatorial Chemistry, 2006